Spore Powder of Ganoderma Lucidum for the Treatment of Alzheimer Disease: A Pilot Study

Authors: Guo-hui Wang, Li-hua Wang, Chen Wang, Li-hong Qin

Journal: Medicine (Baltimore)

Study Design:

• Intervention: Spore Powder of Ganoderma Lucidum (SPGL) or placebo
• Participants: 42 patients with Alzheimer’s disease (AD)
• Duration: 6 weeks
• Outcome Measures:
  • Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-cog)
  • World Health Organization Quality of Life questionnaire (WHOQOL-BREF)
  • Neuropsychiatric Index (NPI)

Summary: This pilot study investigated the effects of SPGL on cognitive function, quality of life, and neuropsychiatric symptoms in patients with AD. After 6 weeks of treatment, there were no significant differences between the SPGL and placebo groups in any of the outcome measures. This suggests that SPGL may not be effective for the treatment of AD, at least in the short term. However, the study had limitations, including a small sample size and short duration, so further research is needed to confirm these findings.